Health and Fitness Health and Fitness
Tue, October 9, 2012
Mon, October 8, 2012
Sun, October 7, 2012
Sat, October 6, 2012
Fri, October 5, 2012
Thu, October 4, 2012
Wed, October 3, 2012
Tue, October 2, 2012
Mon, October 1, 2012
Sun, September 30, 2012
Sat, September 29, 2012
Fri, September 28, 2012
[ Fri, Sep 28th 2012 ] - Market Wire
call for signatures
Thu, September 27, 2012
[ Thu, Sep 27th 2012 ] - Market Wire
30 a.m. Eastern
Wed, September 26, 2012
Tue, September 25, 2012

Law Offices of Howard G. Smith Announces Investigation of Peregrine Pharmaceuticals, Inc.


//health-fitness.news-articles.net/content/2012/ .. estigation-of-peregrine-pharmaceuticals-inc.html
Published in Health and Fitness on Monday, October 1st 2012 at 15:31 GMT by Market Wire   Print publication without navigation


BENSALEM, Pa.--([ ])--Law Offices of Howard G. Smith announces that it is investigating potential claims against Peregrine Pharmaceuticals, Inc. (aPeregrinea or the aCompanya) (NASDAQ:PPHM) concerning possible violations of federal securities laws. The investigation is related to allegations that certain statements issued by the Company between September 7, 2012 and September 21, 2012 concerning the Companyas business and financial prospects were false and misleading.

Peregrine is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials focused on the treatment and diagnosis of cancer. The Company is pursuing multiple clinical programs in cancer with its lead product candidate, bavituximab, and novel brain cancer agent Cotara. The investigation concerns allegations that the Company and certain of its executive officers violated federal securities laws by misrepresenting or failing to disclose material adverse facts about Peregrineas business and financial prospects, including: (1) that clinical data from the Companyas randomized, double-blind placebo-controlled Phase II trial of bavituximab in second-line non-small cell lung cancer was unreliable; (2) that there were major discrepancies between some patient sample test results and patient treatment code assignments; and (3), that the Companyas positive statements about its business, operations and prospects lacked a reasonable basis -- including those statements relating to the clinical data from the Companyas randomized, double-blind placebo-controlled Phase II trial of bavituximab in second-line non-small cell lung cancer.

If you purchased Peregrine securities between September 7, 2012 and September 21, 2012, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to [ howardsmith@howardsmithlaw.com ], or visit our website at [ http://www.howardsmithlaw.com ].


Publication Contributing Sources